19:08 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Infectious Cell culture and mouse studies suggest inhibiting DC-SIGN could help treat schistosomiasis. In spleen, mesenteric lymph node and granuloma cells from a mouse model of schistosomiasis co-cultured with Schistosoma mansoni eggs, knockout of...
07:00 , May 23, 2016 |  BioCentury  |  Product Development

Provoking a response

Gritstone Oncology Inc. selected Immune Design Corp .'s ZVex technology to deliver personalized neoantigen therapies because targeting the antigens directly to dendritic cells with a viral vector could be the most immunogenic approach. Gritstone launched...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN; CD209)

Infectious disease INDICATION: Ebola Cell culture studies identified a DC-SIGN-binding glycofullerene that could help treat Ebola. The compound consisted of a core 60-carbon fullerene ([60]fullerene) linked to 12 additional [60]fullerenes, each conjugated to 10 molecules...
07:00 , Aug 6, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN; CD209)

Pulmonary disease INDICATION: Pulmonary fibrosis Mouse studies suggest activating DC-SIGN could help treat pulmonary fibrosis and other fibrotic diseases. In a mouse model of acute lung inflammation, a small molecule activator of DC-SIGN decreased neutrophil...
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Investing by design

Sanofi -Genzyme BioVentures hopes last week's investment in the $32.5 million first close of immunotherapy play Immune Design Corp. 's planned $49 million series C round will advance the fund's goal of filling parent Sanofi's...
07:00 , Jun 6, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN; CD209) Cell culture and mouse studies identified DC-SIGN-binding mannodendrimers that could help treat inflammatory diseases. Mannodendrimers are comprised...
07:00 , Sep 4, 2008 |  BC Innovations  |  Targets & Mechanisms

New Sine Qua Non for CMV

Platelet derived growth factor receptor A has been a cancer target since the 2001 approval of Novartis AG 's leukemia drug Gleevec , an inhibitor of several Bcr-Abl tyrosine kinase receptors. Now, the pharma company...
07:00 , Mar 27, 2008 |  BC Innovations  |  Cover Story

Antigens by Special Delivery

DNA vaccines often require high and repeated dosing of antigen, which suggests suboptimal priming of the immune system and results in weak immunogenicity. 1 Separate papers in Nature Biotechnology and the Journal of Clinical Investigation...
07:00 , Mar 13, 2008 |  BC Innovations  |  Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Dendritic cell (DC)-based immunization In vivo data suggest retroviral delivery of antigenic genes specifically to DCs may be more cost effective and less...
08:00 , Feb 14, 2008 |  BC Innovations  |  Cover Story

New roadblock to HIV infection

The goal of developing an effective vaginal microbicide against HIV infection has eluded researchers ever since the first potential compound assessed, nonoxynol-9, proved to actually increase infection rates. In the Proceedings of the National Academy...